Navigation Links
CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
Date:2/7/2008

r certain heart defects, CryoValve SG may give these kids a great opportunity to live active, normal lives. As a surgeon, I'm very excited to be able to offer them and their families this treatment option."

At FDA's request, CryoLife is planning a post-clearance study to seek evidence for the potential and implied long-term benefits of the SynerGraft process. Data to be collected is expected to include long-term safety and hemodynamic function, immune response, and explant analysis. CryoLife believes that this information may help it ascertain whether the SynerGraft process reduces the immunogenicity of the transplanted heart valve and recellularizes with the recipients own cells.

CryoLife will be using the SynerGraft technology for the majority of its pulmonary valve processing and anticipates that the first CryoValve SG may be available for shipment late in the first quarter of 2008.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding anticipated effectiveness, benefits and indications for use of CryoValve SG as well as the timing of use of the SynerGraft technology. These
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CryoLife Names Philip Theodore as Vice President, General Counsel
2. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
3. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
4. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
5. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
6. CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
7. CryoLife to Present at OneMedPlace Finance Forum
8. CryoLife Announces Record Preservation Services and Product Revenues for 2007
9. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
10. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
11. CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... (PRWEB) May 28, 2015 DryLet, ... use in applications such as animal waste reduction, ... oil reduction in wastewater treatment plants and restaurant ... the World Pork Expo, June 3-5 in Des ... year in a Wall Street Journal article because ...
(Date:5/28/2015)... N.J. , May 28, 2015  PDS ... a cancer immunotherapy treatment targeting HPV-16, has generated ... Currently, pre-cervical cancer is treated by ... a simple and effective non-surgical alternative. Results show ... mechanisms (T-cells) to recognize, target, and kill precancerous ...
(Date:5/28/2015)... 2015 Biscayne Pharmaceuticals, Inc ., today ... growth hormone-releasing hormone (GHRH) technology will be discussed in a ... Meeting. The data show that the family of receptors ... is present on many primary breast cancer cells regardless ... antagonists could have broad anti-cancer potential in breast cancer. ...
(Date:5/28/2015)... and London (PRWEB) May 28, 2015 ... of Computer Aided Engineering software, announced today it ... Inc. (PSRI). CD-adapco will provide state-of-the-art engineering simulation ... will share their expertise and experiences in analyzing ... refining industry members and advance the understanding of ...
Breaking Biology Technology:DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... Visionsense Corp. announces,FDA 510(k) Clearance of ... The system is based on a miniature ... Minimal Invasive,laparoscopic and endoscopic Surgery (MIS)., ... MIS surgical,procedures that are under served by ...
... Therapeutics announced today,the initiation of a Phase ... orally bioavailable small molecule in development for ... I study will evaluate the safety,tolerability and ... blind, placebo controlled, single ascending dose design ...
... March 18 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ... II study of,NGX267, a muscarinic agonist in development ... The company is conducting a randomized, double-blind,placebo-controlled, ... evaluate,the safety, tolerability and efficacy of this once-a-day ...
Cached Biology Technology:Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... As drylands of the world become even drier, water will not ... the soil will likely be affected, and their imbalance could affect ... That includes people living in Arizona, who may be in for ... study published in Nature that details how soil changes ...
... teams at the Polytechnic Institute of New York University ... understand and influence the complex swimming behaviors of schooling ... of mechanical and aerospace engineering at NYU-Poly, published two ... These studies are the latest in a ...
... scent marking to advertise their territory they urinate at ... It has been suggested that markings serves to attract females ... males, scent marks appear to be a secondary sexual trait, ... mate. When male house mice are subordinate or sick, for ...
Cached Biology News:Plant production could decline as climate change affects soil nutrients 2The secret's in the (robotic) stroke 2The secret's in the (robotic) stroke 3Scent marking 2
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... are derived from the Spodoptera frugiperda Sf21 cell ... in transfections, plaque assays, virus production, and protein ... that optimizes recovery of viable cells after thawing. ... Insect Cell Medium and can also be grown ...
...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This cloning ...
Biology Products: